RESEARCH MONOGRAPH · KDC-MN-074

Memantine

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 2 min read

Our opinion on this compound

82/100

The uncompetitive NMDA antagonist that quietly does interesting things beyond Alzheimers, and most people miss it

Memantine is the kind of established workhorse that gets dismissed because it's been around forever (originally developed at Eli Lilly in the 60s as an influenza drug, of all things, and repurposed for dementia in Germany since the 80s). The mechanism is genuinely clever and worth respecting: uncompetitive low-affinity voltage-dependent NMDA receptor antagonism with fast off-kinetics.

Here's why that matters. Pathological NMDA activation in neurodegeneration involves prolonged moderate calcium influx, while physiological synaptic NMDA signaling involves brief high-magnitude events. Memantine's fast off-kinetics mean it preferentially blocks the pathological tonic activation while letting normal phasic synaptic transmission through. That's a remarkable bit of receptor pharmacology and a paper-worthy mechanism on its own.

What we like: the Alzheimers effect size is real but modest, and that's not actually the interesting part. The off-label and research literature on memantine in tinnitus, OCD with autism features, neuropathic pain, alcohol craving, and as an adjunct in ketamine-resistant depression is genuinely intriguing. The Krystal group at Yale has done some thoughtful work on memantine in psychiatric indications. Plus the pharmacokinetics are unusually clean: oral bioavailability near 100%, predictable half-life, minimal CYP metabolism.

What we dont like: the marketing around memantine in dementia oversold a real but small clinical effect, which damaged the credibility of the underlying mechanism story. And the obsession with combining donepezil + memantine in Alzheimers (the "Namzaric" formulation) didn't deliver the synergy people hoped for.

Sourcing is essentially perfect. It's a small simple adamantanamine, pharmacopoeia-grade material is widely available, generic prices are low, and the HCl salt is stable and easy to handle. This is the kind of compound where research-grade and pharmaceutical-grade overlap closely.

For studying NMDA receptor pharmacology, off-label psychiatric indications, or glutamate-mediated neuroprotection, memantine is one of the most useful and underappreciated tools in the cabinet. The story is bigger than the Alzheimers indication suggests.

Evidence: 85
Mechanism: 88
Reliability: 80
Safety: 85
Sourcing: 92
Value: 80
Signal: 72
Staying power: 75

Plain-language summary Intrigue 72 / 100

Memantine, sold as Namenda, is an Alzheimer disease medication that blocks the NMDA glutamate receptor. Unlike most NMDA antagonists it has a brief, low-affinity profile that allows normal learning while preventing the chronic excitotoxicity associated with neurodegeneration. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

NMDA receptor antagonist (uncompetitive low-affinity)

An adamantane-derived uncompetitive low-affinity NMDA antagonist FDA-approved as Namenda for moderate-to-severe Alzheimer disease.

Abstract

Memantine (Namenda, Axura, Ebixa; 1-amino-3,5-dimethyladamantane; CAS 19982-08-2; molecular formula C12H21N; molecular weight 179.30) is a low-affinity uncompetitive NMDA receptor antagonist approved by the FDA in 2003 for moderate-to-severe Alzheimer disease. The compound is structurally related to amantadine. The low-affinity, voltage-dependent block of NMDA receptors allows physiological glutamate signaling to proceed while preferentially blocking pathological excitotoxic activation. Pharmacokinetics: plasma half-life 60 to 80 hours; minimal hepatic metabolism; renally excreted. Reported research dose ranges in the literature are described in the source monograph. Often used in combination with AChE inhibitors. The clinical evidence base shows modest but consistent improvements in cognitive and functional measures in moderate-to-severe Alzheimer disease.

Mechanism of action

Uncompetitive low-affinity NMDA antagonist; voltage-dependent block. Spares physiological glutamate signaling.

Reported research dose ranges

5 to 20 mg (reported research dose range).

References

Reisberg B, et al. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 2003.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, reported research dose ranges, sourcing and quality verification, reconstitution and handling, stack interaction considerations, and a curated reference list. Available as a research-use-only PDF download.

KDC-MN-074

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

Memantine

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs